cyclosporine rheum
Selected indexed studies
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (Ann Rheum Dis, 2024) [PMID:37827694]
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. (Ann Rheum Dis, 2024) [PMID:39317417]
- EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. (Ann Rheum Dis, 2020) [PMID:31672775]
_Worker-drafted node — pending editorial review._
Connections
cyclosporine rheum is a side effect of
Sources
- EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. (2020) pubmed
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. (2025) pubmed
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. (2024) pubmed
- Environmental Triggers of Hyperuricemia and Gout. (2022) pubmed
- Consensus-based recommendations for the management of juvenile dermatomyositis. (2017) pubmed
- Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. (2024) pubmed
- Efficacy and safety of emapalumab in macrophage activation syndrome. (2023) pubmed
- The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. (2016) pubmed
- Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease. (2024) pubmed